Evaluation of the Efficacy of a CD122 Biased Agonist for Treatment of Melanoma as a Monotherapy and in Combination with PD-1 Inhibition Using a Mechanistic Physiological Model
Presented by Nektar and Rosa at the American Conference on Pharmacometrics (ACoP), 2018.
Development of the Respiratory PhysioPD Platform, a QSP Model to Investigate Biological Mechanisms Underlying Bronchoconstriction
Presented by Boehringer Ingelheim and Rosa at the American Conference on Pharmacometrics (ACoP), 2018.
Quantitative Systems Pharmacology Model to Quantify Benefits of DAAO Inhibition in Schizophrenia
Presented by Takeda and Rosa at the American Conference on Pharmacometrics (ACoP), 2018.
Development of a Psoriasis PhysioPD Platform to Evaluate a Novel Therapy and Identify Uncertainties Critical to Efficacy and Competitive Differentiation
Presented by Grunenthal and Rosa at the American Conference on Pharmacometrics (ACoP), 2018.
PhysioPD Research Utilizes Mechanistic Physiological Models to Enhance Immunology Research and Drug Development
Presented by Rosa at the Quantitative Systems Pharmacology Day (QSP Day), 2018.
Using a Quantitative Systems Pharmacology PhysioPD Platform to Investigate Causes of Adverse GI Events Associated with Prolonged Treatment with PI3-Kinase Inhibitors
Presented by Genentech and Rosa at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) conference, 2018.
Using Mechanistic Physiological Models to Enhance Oncology Research and Drug Development
Presented by CMIC Holdings and Rosa at the 32th Annual meeting of Japanese Society for the Study of Xenobiotics (JSSX), November 29- December 1, 2017, Tokyo, Japan; summarized in Japanese in the JSSX Newsletter, Volume 33, number 2, 2018. (In Japanese and for JSSX members only)
